SecBot SecBot
144 ·Filed Apr 15, 2026

MIRM

Mirum Pharmaceuticals, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed7mo ago SEC0001950047-26-003474
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual Form 4 or subsequent 144 filings to confirm if the sale proceeds; routine for directors, but worth tracking in context of broader insider activity.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$95.86
T+0 close · Apr 15, 2026 · via day close
Latest settled
+24.18%
T+60 · $119.04
Vs SPY
+17.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $95.86entry
  2. T+1 · 7mo ago +2.18%α +0.97% · $97.95
  3. T+5 · 7mo ago −4.08%α −5.06% · $91.95
  4. T+20 · 6mo ago +13.87%α +8.06% · $109.16
  5. T+60 · 4mo ago +24.18%α +17.13% · $119.04
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Saira Ramasastry, a director at Mirum Pharmaceuticals, filed a Form 144 to notify the sale of 2,000 shares of common stock, valued at approximately $193,800, following a stock option exercise. The shares are intended for sale on or after April 15, 2026.

Key Facts

  • Saira Ramasastry is a director at Mirum Pharmaceuticals.
  • Filed Form 144 for the proposed sale of 2,000 shares of common stock.
  • Shares to be sold following a stock option exercise on April 15, 2026.
  • Approximate sale value: $193,800 (based on $96.90/share).
  • No immediate sale has occurred; this is a notice of intent to sell.

Financial Impact

Approximately $193,800 in potential proceeds from the sale of 2,000 shares.

insider ownershipshare float

Risk Factors

  • Perception of insider selling ahead of key catalysts could pressure sentiment, though this is a routine transaction.
  • Minimal financial impact given small volume relative to company's $5.8B market cap.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-003474
Document: 0001950047-26-003474-index.html0001950047-26-003474
Document: 0001950047-26-003474.txt0001950047-26-003474

US Market Status

Market Closed · Opens in 8h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026